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Acute myeloid leukemia (AML) is a rather common disease, characterized by the presence of a clonal population of
hematopoietic progenitor cells with impaired differentiation. Although traditionally AML has been considered the
result of genetic alterations, more recently experimental evidence have demonstrated that epigenetic modifications
are important in development and maintenance of leukemia cells. In this review we summarize current scientific
knowledge of epigenetic alterations involved in leukemogenesis. We also highlight the developing of new
technological strategies that are based on epigenetic processes and have been registered as Patents of Inventions
in the United Nations dependent World Intellectual Property Office (WIPO) and the main Patent offices worldwide.Introduction
The World Health Organization (WHO) defines acute
myeloid leukemia (AML) as a heterogeneous clonal dis-
order of hematopoietic progenitor cells (“blasts”), which
exhibit impaired maturation [1]. AML is the most com-
mon acute leukemia in adults and, in the absence of treat-
ment, this alteration in blood cells leads to dead typically
within 1 year of diagnosis mainly by infection, bleeding, or
organ infiltration. Until now, treatment of AML consists
of cytotoxic “chemotherapy” and might cure 20–75% of
patients younger than 60 years depending primarily on
leukemia-cell cytogenetics. However, in elderly patients
despite achievement of reasonable complete response
rates (CR rates 35%-55%), intensive chemotherapy is asso-
ciated with a high incidence of 4-week mortality and with
3- to 5-year survival rates of < 10% [2-4]. Currently is esti-
mated that 7.820 men and 6.770 women will be diagnosed
and 10.370 (men and women) will die of AML in 2013 in
US. The majority of the AML cases are associated with
nonrandom chromosomal translocations. Although over
700 recurrent aberrations have been described associated
with the AML phenotype, the four more common are:
t(15; 17)/PML-RAR, t (8;21)/AML1-ETO. Inv(16)/core
binding factor (CBF)b-MYH11, 11q23 and mixed lineage
leukemia (MLL)-fusion proteins.* Correspondence: sgutierr@udec.cl
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distribution, and reproduction in any mediumTraditionally AML has been considered the result of
genetic alterations leading to irreversible defects of critical
gene functions such as proliferation, differentiation, apop-
tosis and gene transcription associated to leukemogenesis.
The mutated genes are often grouped in two classes: genes
which confer a growth advantage by activating down-
stream effectors of various signaling pathways (including
members of the signal transducer and activator of tran-
scription (STAT), PI3K and RAS–MAPK pathways) and
genes which alter the expression of key transcriptional
targets in myelopoiesis (e.g. PML, RUNX1, MLL). In all
cases, the end result is that the affected cell loses the
ability to differentiate and to respond to cell proliferation
regulators. DNA in human cells is found associated to
proteins forming the chromatin. Packing eukaryotic ge-
nomes into high-order chromatin structures is critical for
controlling most, if not all, processes derived from DNA.
The minimal repeating unit of chromatin is the nucleo-
some, comprised of 147 base pairs wrapped around a
histone octamer core [5]. In comparison to “naked” DNA,
nucleosomal DNA is less accessible for DNA-binding pro-
teins such as transcription factors, DNA replication and
DNA repair complexes. Nucleosome cores are connected
by linker DNA sequences of variable length to give an
average DNA length of approximately 200 bp. Arrays of
11-nm nucleosomes are thought to condense into ap-
proximately 30-nm fibers. A fifth histone, the linker
histone H1, is structurally distinct from other histones and
it has been shown that facilitates compaction of nucleo-
somes into 30-nm fibers and higher order chromatinioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mechanism for controlling transcription and other
processes that utilize DNA as template [6]. The changes
between tightly packed DNA (heterochromatin) and
exposed DNA (euchromatin) are coordinated through
modifications of the nucleosome structure either by DNA
methylation, histone post-translational modifications (e.g.
acetylation, methylation) or by ATP-dependent chromatin
remodeling complexes (a group of protein complexes that
can slide nucleosomes on DNA or bring about the
exchange or eviction of the histones). These heritable
changes in DNA packing that regulate DNA transcrip-
tional activity are collectively known as epigenetic modifi-
cations. In the past few years, several reports have linked
the development of the AML phenotype to epigenetic
alterations [7-9]. For instance, recent genome-wide and
candidate-gene studies have identified somatic alterations
in genes that encode proteins regulating DNA methylation
and post-translational histone modifications. These data
suggest that somatic alterations in epigenetic regulators
are a common genetic event in AML and contribute to
hematopoietic cell transformation. In fact, epigenetic
changes play a crucial role in the regulation of gene
expression and several studies have reported epigenetic
abnormalities occurring within signaling pathways regulat-
ing proliferation, migration, growth, differentiation, tran-
scription, and death signals that may be critical in the
establishment and progression of malignancies [10]. This
data are underscored by recent studies which suggest that
mutations in a subset of epigenetic regulators, including
TET2 (Ten eleven Translocation protein 2), ASXL1
(Additional Sex Combs protein 1) and DNA methyl
transferase 3a (DNMT3a) [11-14], are associated with
poor overall survival of AML patients; therefore, defin-
ing a new subset of high-risk leukemia that is in need of
novel, mechanism-based therapies. More importantly,
because the epigenetic modifications are reversible,
therapies based in epigenetic modifiers hold the promise
of being highly effective. In this review we will discuss
recent data implicating epigenetic alterations in the patho-
genesis of AML, risk stratification and therapeutic of
patients with myeloid leukemia; patents applications
presented worldwide related with epigenetic modifiers or
modifications are also summarized.
Epigenetics
As mentioned above, epigenetics is defined as the study
of heritable changes in gene expression that are not due
to modifications in the DNA sequence. Epigenetic
changes can be established through multiple molecular
mechanisms that include DNA methylation, histone
modifications and more recently, the action of small
RNA that do not codify for a protein or polypeptide but
can regulate gene expression, known as non-codingRNAs (ncRNA). All of these different modifications are
closely interrelated and can influence each other. Inter-
estingly, epigenomic profiling studies of patients with
AML have revealed alterations in DNA methylation
[15,16], oxidized derivatives of methylated cytosines [17],
and alterations in histone post-translational modifica-
tions such as lysine methylation [18,19], phosphorylation
[20], and acetylation [21,22], suggesting a fundamental
role for these modifitions in AML pathogenesis.
DNA methylation
In eukaryotes, ranging from plants to humans, DNA
methylation is found exclusively at cytosine residues,
which most commonly are forming part of a CpG di-
nucleotide. The CpG dinucleotides are not homoge-
neously distributed throughout the genome, normally
they are clustered in short DNA regions highly rich in
CpG that are known as CpG islands, and in highly re-
petitive regions such as centromers and retrotranposons
[23,24]. Approximately 60% of the human genes have
CpG islands in their regulatory regions (promoters) [25].
In the human genome there are about 13,000 CpG islands
that are constitutively unmethylated [26]. However, a
small but significant proportion of all CpG islands become
methylated during development and when this happens
the associated promoter is stably silent. Developmentally
programmed CpG-island methylation of this kind is
involved in genomic imprinting and X chromosome
inactivation [23]. In contrast, most of the genomic CpG
dinucleotides are methylated in all tissues and is thought
to play a role in suppressing recognition of spurious intra-
genic DNA-binding sites to protect the cell from uncon-
trolled transcriptional activity and genomic instability [27].
DNA methylation results in stabilization of transcrip-
tional repression and loss of gene function when present
in promoters [23,28,29]; however, is associated with
active expression when present into the genes (exons +
introns) [30,31]. It has been suggested that these diver-
gent relationships of DNA methylation with gene
expression could be driven by a common role of DNA
methylation in the stabilization of nucleosomes and in
the occlusion of the transcriptional initiation site. Like-
wise, the introduction of a methyl group to the DNA
can directly alter the binding of transcription factors
[23,32,33], further buffering against recognition of intra-
genic DNA-binding sites in actively expressed genes.
Alternatively, DNA methylation may create new binding
sites for proteins with methylation recognition domains
which in turn induce gene repression by recruiting
histone deacetylases (HDACs) [34,35].
DNA methylation occurs within CpG dinucleotides
through addition of a methyl group at the 5′ position of
the cytosine ring, forming 5-methyl cytosine, in a reac-
tion catalyzed by enzymes known as DNA methyl
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methyltransferases: DNMT1, DNMT3a and DNMT3b.
DNMT1 is the primary maintenance enzyme that pre-
serves existing methylation patterns following DNA
replication by adding methyl groups to corresponding
daughter strands at the hemi-methylated CpG sites.
DNMT3a and DNMT3b are methyltransferases that
preferentially target unmethylated CpGs to initiate de novo
methylation and therefore, they are highly expressed
during embryogenesis but minimally expressed in adult
tissues. A fourth family member, DNMT-3 L, lacks in-
trinsic methyltransferase activity; however it facilitates
methylation of retrotransposons by interaction with
DNMT3a and 3b [37].
DNA methylation is the most studied epigenetic alter-
ation in cancer and was the first epigenetic alteration to
be connected to its development [38,39]. CpG island
methylation is now widely recognized to be associated
with cancer-related changes in gene expression. These
changes are produced mainly through three different
mechanisms: hypomethylation, loss of imprinting, and
hypermethylation. As mentioned above, in addition to
regulation by DNA methylation itself, methylated DNA
binding proteins (MBDs) can bind to methylated cyto-
sine, and sequentially form a complex with histone
deacetylase (HDAC) leading to chromatin compaction
and gene silencing [40].
Global hypomethylation can lead to chromosomal
instability, mutations and reactivation of various onco-
genes. For instance, DNMT1 is responsible for the es-
tablishment of the DNA methylation pattern during
DNA synthesis, and its deficiency in cells may lead to
global hypomethylation. Another common alteration
observed in cancer cells is DNA hypermethylation of
promoter-associated CpG islands of tumor suppressor
genes, which could serves as a surrogate for point muta-
tions or deletions to cause transcriptional silencing of
these genes [41,42].
A detailed study on the genomic methylation landscape
of AML [43] have identified 16 distinct methylation
patterns; each of these DNA-methylation AML subtypes
displayed a unique epigenetic signature when compared
with normal bone marrow CD34+ cells. These patterns
most accurately overlapped with the currently known mo-
lecular subtypes of AML while simultaneously revealed
the existence of additional epigenetic differences among
patients. In fact, three of the 16 patients clusters corres-
pond to AML subtypes defined by WHO: t(8;21), inv(16)
and t(15;17). Although this finding was perhaps expected,
it is an important validation of the use of large-scale
genome-wide DNA methylation profiling technology.
Moreover, their data are consistent with the hypothesis
that each of these fusion oncoproteins can drive the
establishment of a specific epigenetic patterning inhematopoietic cells. Notably, this analysis also defined five
new AML subtypes that could not be explained by any
known morphologic, cytogenetic, or molecular feature. In
fact, each of these AML subtypes displays an unique and
significantly different epigenetic signature when compared
to normal CD34+ control cells and a significant difference
in patient survival was observed between these novel
AML subtypes. Taken together, these results indicate that
DNA methylation profiling identified clinically relevant
AML subtypes that cannot be captured by any of the
currently available diagnostic method.
Surprisingly, in this work the authors show that not all
the identified methylated genes are repress at the expres-
sion level suggesting that other factor(s) may be still
needed to silence them or alternatively that promoter
methylation-mediated silencing is overcome by another
mechanism [43].
The methylation profiles identified by Figueroa et al [43]
support the idea that AML patients can be identified by a
core set of genes that are commonly methylated in AML
cells compared with normal hematopoietic cells. Moreover
and more importantly, their results suggest that genomic
methylation markers can be used for improved molecular
classification and may have prognostic value for AML.
A novel class of point mutation described in AML af-
fects the isocitrate dehydrogenase (IDH) genes [44-46].
The two enzymes affected (IDH1 and IDH2), normally
catalyze the oxidative decarboxylation of isocitrate to
α-ketoglutarate and reduce NADP to NADPH. The
point mutations cause loss of native enzymatic activ-
ities and confer novel enzymatic activity, catalyzing the
conversion of α-ketoglutarate to 2-hydroxyglutarate
(2-HG), an oncometabolite. 2‑HG is present at mark-
edly elevated levels in the serum of patients with AML
harboring IDH1 or IDH2 mutations, suggesting that
2‑HG could be a biomarker for IDH-mutant AML [46].
All known mutations involve arginine (R), in codon 132 of
IDH1 or codon 140 or 172 of IDH2. Although mutations
of R140 in IDH2 exclusively result in the substitution of
arginine to glutamine (IDH2‑R140Q), mutations affecting
IDH1‑R132 or IDH2‑R172 consist of a broader range of
amino-acid substitutions (IDH1‑R132H, IDH1‑R132C,
IDH2‑R172K, IDH2‑R172M and IDH2‑R172S). IDH1
(R132) and IDH2 (R140) mutations are frequently ac-
companied by normal cytogenetics and nucleophosmin
(NPM1) mutation, whereas IDH2(R172) is frequently the
only mutation detected in AML. Moreover, mutational
and methylation studies of a large cohort of AML patients
demonstrate that IDH and TET2 mutations are mutually
exclusive in AML and that patients with mutation in ei-
ther IDH or TET2 genes exhibit similar methylation pro-
files characterized by global promoter hypermethylation
[47]. Subsequent biochemical studies demonstrated that
2-HG inhibits TET family members, as α ketoglutarate
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is reduced by the production of 2-HG [48,49]. TET pro-
teins are dioxygenases that catalyze the conversion of 5
methyl cytosine (5mC) to 5 hydroxyl methyl cytosine
(5hmC) [50]. Tet proteins can further oxidize 5hmC to
generate 5-formylcytosine (5fC) and 5-carboxylcytosine
(5caC), which can then be removed from the genome by
thymine-DNA glycosylase (TDG) [51-53]. This suggests
that 5hmC may act as a DNA demethylation intermediate.
TET2 is often silenced or mutated in myelo proliferative
disease (MPD), myelodysplastic syndrome (MDS), chronic
myelomonocytic leukemia (CMML) and lymphomas
suggesting a tumor suppressor role for TET2 in myeloid
tumors, MPD and MDS. 5hmC not only impairs the bind-
ing of 5mC binding proteins [54], but has its own binding
proteins [55] and shows unique distribution patterns in
the genome [56,57], suggesting that 5hmC may serve as
an epigenetic mark with different regulatory functions.
Mutations in TET2, IDH1 or IDH2 seem to have clinical
relevance to risk stratification and/or therapeutic rele-
vance in patients with AML. In fact, mutations in TET2
confer adverse overall survival in intermediate risk-subset
of AML regardless of fms-related tyrosine kinase gene
(FLT3) mutational status [58]. However, prognostic impact
of IDH1/2 mutations seems to vary according to the spe-
cific mutation and also depends on the context of concur-
rent mutations of other genes. For instance, IDH2(R172)
mutations confer a poor prognosis in AML patients, while
IDH1(R132) mutation may predict poor outcome only in
a subset of patients with molecular low-risk AML [59]. As
mentioned above, the mutations in IDH generate a new
enzymatic activity which result in 2-HG production
affecting the enzymatic activity of the TET family;
however, there are other α ketoglutarate-dependent
enzymes that may also be inhibited by 2-HG affecting
the cell epigenetic state including members of the
jumonji-domain-containing (JMJC) family of histone
lysine demethylases, which demethylate lysines 9 and
36 of histone H3 (H3K9 and H3K36) [60].
More recently, two reports found that the (R)-enantio-
mer of 2-HG ((R)-2HG) may actually serve as a cofactor
for the activation of the Egl-Nine (EGLN) family of prolyl
hydroxylases (EGLN1–3) [61,62]. In both reports, the au-
thors found that oncogenicity of IDH1 mutants in neural
and hematopoietic cells may depend on the increased ac-
tivity of the EGLN family, which normally mark the
oxygen-labile subunit of the transcription factor hypoxia-
inducible factor (HIF) for proteasomal degradation. These
data suggest that therapeutic targeting of the EGLN family
may also be useful in the treatment of IDH-mutant AML.
Histone modifications
The major sites for histone posttranslational modifications
are located in the N-termini of the histone proteins,known as ‘histone tails,’ which extend from the histone
octamer of the nucleosome core (Figure 1). Histone may
undergo several post-translational modifications, which
can alter chromatin dynamics either by providing recog-
nition sites for specific proteins (or protein complexes)
or changing the nucleosome structure by altering elec-
trostatic charge [63]. Histone modifications include
acetylation, methylation, phosphorylation, sumoylation,
ubiquitination, ribosylation and also proline isomeriza-
tion. In most cases, the enzymes that carry out these
functions are part of multiprotein complexes involved in
some aspect of gene regulation or other genomic func-
tions. According to the experimental evidence available,
most of the histone tails modifications appear to have little
effect in the internal structure of the nucleosome core
[64]; however, they do affect interactions of nucleosomes
with transcription factors and other nucleosomes. More
recently, the characterization of bulkier histone modifica-
tions or modifications within internal histone domains has
been suggested to potentially impact nucleosome structure
[65]. Among the histone covalent modifications, the most
studied are the acetylation in lysine (Figure 2) and the
methylation in lysine and arginine residues (Figure 3) of
histones H3 and H4, mainly in relation to their role in
transcriptional regulation. In general, while histone acetyl-
ation is related to open chromatin structure, and therefore
activation of gene transcription, histone methylation is
found mostly associated with closed chromatin and tran-
scriptional repression.
The enzymes that participate in establishing these
histone modifications are the histone acetyltransferases
(HAT) and the histone methyl tranferases (HMT) com-
plexes, respectively; while the removal of the modifications
are carried out by histone deacetylases (HDACs) and his-
tone demethylases (HDMTs). Although the heritability of
histone modifications themselves is not completely
established, a great number of epigenetic cell memory pro-
teins that have been implicated in human disease have also
turned out to be enzymes that are involved in modify or
recognize histone modifications [21,66-68].
Histone acetylation
In addition to their effect on histone-DNA interaction,
individual histone modifications can enhance or de-
crease the presence of another modification on a target
gene, they can also interact with signaling pathways
and with other epigenetic regulators such as DNA
methylation, and noncoding RNAs (ncRNAs). This ex-
perimental evidence has led to the proposal of a
histone code, which would be read by specific proteins
or proteins complexes for the epigenetic regulation of
gene expression [69,70]. Central to the establishment
of the histone code, is the activity of HAT and HDAC
enzymes. In fact, some HATs are recurrent components of
ARTKYTARKSTGGKAPRKQLATKAARKSAPATGGVKKN- K56,79
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Figure 1 Histone post-translational modifications. Top panel correspond to a diagrammatic representation of a nucleosome showing histone
H3 and H4 N-terminus (histone tails), which extend from the nucleosome particle. Bottom panel show some of the specific amino-acid residues
that are methylated and/or acetylated in the N-terminus of histone H3 and H4 as well as some of the residues modified in the histones
globular domain.
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arrangement in leukemia, for example t(8;16)(p11,p13)
associated with AML generate the fusion protein MOZ-
CBP which is composed for two HAT enzymes: MOZ
(MOnocytic leukemia Zinc-finger protein) and CBP (CREB-
Binding Protein). The different fusion proteins contrib-
ute to leukemic transformation most likely by a mechan-














Figure 2 Histone acetylation. Histone acetyltransferase complexes (HATs
ε-amino of a lysine residue. Removal of an acetyl group from a ε-N-acetyl l
deacetylase complexes (HDACs). Curly lines represent the rest of the proteiaberrant activation of gene expression [71,72]. Moreover,
in a recent study, inactivating mutations within the HAT
domain of CBP have been found in approximately
18% of relapsed AML cases, suggesting that the im-
paired HATactivity could be linked to resistant to therapy
in AML [22].
It has also been proposed that aberrant recruitment of
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Figure 3 Histones can only be methylated on lysine (K) and arginine (R) residues. A) Lysine is able to be mono-, di-, or trimethylated with
a methyl group replacing each hydrogen of its NH3+ group. B) Arginine, with a free NH2 and NH2+ groups, is able to be mono- or
dimethylated. Arginine methylation can be asymmetric on the NH2 group or symmetric with one methyl on each group. Specific histone methyl
transferases (HMT) and histone demethylases (HDM) catalyze these processes. Curly lines represent the rest of the protein molecule.
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lying a broader group of AMLs. Indeed, the AML1-ETO
fusion protein was demonstrated to act through an aberrant
HDAC-recruiting mechanism that leads to the block of
hematopoietic differentiation [73]. Altered distribution of
HDAC1 in AML and consequent specific pattern of chro-
matin modifications at hematopoietic genes could also be
associated with the patient’s outcome, and thus be a tool to
improve prognosis prediction [74]. Interestingly, the impli-
cations of HDACs in leukemia is not limited to their aber-
rant recruitment by fusion proteins [75-77], as alterations
in the expression of various HDAC isoforms have also been
associated with the patient’s prognosis [78].
Histone methylation
MLL (Mixed Lineage Leukemia protein) is a histone
methyltransferase required for the epigenetic mainten-
ance of gene activation during development [79-81]
and is also mutated in a subset of aggressive acute leuke-
mias (both ALL and AML) [82]. MLL maintains geneactivation in part by methylating histone 3 on lysine 4
[83,84]. The most common leukemogenic MLL mutations
are chromosome translocations that fuse the N-terminus
of the MLL gene in-frame with any of more than 70 differ-
ent partner genes producing novel MLL fusion proteins
[85,86]. Interestingly, the leukemias caused by MLL fusion
proteins have very few additional genetic mutations
[87-90], suggesting that the formation of the fusion pro-
tein alone is sufficient for initiating leukemogenesis. The
N-terminus involved in formation of MLL fusion proteins
retains the MLL histone methyltransferase activity and
therefore it seems that the leukemia-causing molecular
mechanism is the aberrant target of epigenetic modifica-
tions. Among the genes misregulated by MLL fusion pro-
teins, the most relevant class is the HOXA family, a group
of genes fundamental in development, which are normally
regulated by MLL and are frequently overexpressed in
leukemia [91]. Recently, Nguyen et al [92] have demon-
strated that MLL-AF9 fusion protein interact with
DOT1L, an H3K79 methyltransferase and this interaction
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AF9–induced leukemogenesis both in vitro and in vivo.
Moreover, through gene expression and chromatin immu-
noprecipitation analysis the authors demonstrated that
mistargeting of DOT1L, result in epigenetic changes at
HOXA genes. In fact, according to their results H3K79
methylation and the consequent up-regulation of HOXA
genes underlie the molecular mechanism of how DOT1L
contributes to MLL-AF9–mediated leukemogenesis. DOT1L
also has been associated to the leukemic transform-
ation by MLL-AF10, MLL-ENL and CALM–AF10, pre-
sumably through the same mechanism [90,93,94].
Although the involvement of histone demethylases
(HDMs) in cancer progression has already been established,
there is no much data regarding their role in leukemia.
Recently it was found that lysine (K)-specific demethylase
2B (KDM2b), a demethylase specific for H3K36me2, is
upregulated in AML and has a critical role both in the initi-
ation and progression of the disease [95].
AML treatment with epigenetics drugs
There are more than 100 epigenetic agents currently
under investigation and a few have received US Food and
Drug Administration (FDA) approval in the last decade.
According to the web site ClinicalTrials.gov, maintained
by the US National Institute of Health and that currently
lists 143,954 studies with locations in all 50 states and in
184 countries, there are 1.818 studies for AML. From the
total number of studies, 608 are open studies defined by
clinical trial web site as: “studies that are currently
recruiting participants, will be recruiting participants in
the future, or involve drugs that are available for expanded
access”. A search for AML and epigenetic retrieved 12
open studies, however searching for DNA methylation
and AML or histone and AML retrieved 24 and 48 studies,
respectively.
Clinical drugs targeting DNA methylation
DNA methyltransferase inhibitors have found the earliest
and greatest success as prototypical epigenetic agents. In
2004, the DNA methyltransferase inhibitor, azacytidine
(VidazaTM), was approved by the FDA for the treatment
of myelodysplastic syndrome MDS, on the basis of
phase II and III clinical trials. In 2006 a second DNA
methyltransferase inhibitor, decitabine (dacogene) received
FDA approval also for treatment of MDS. In these studies,
treatment with decitabine or azacitidine exhibit a response
rate up to 30% that was relatively durable when compared
to placebo [96,97]. Azacitidine is now also being evaluated
in clinical trials on other malignant diseases such as non-
small cell lung cancer and pancreatic cancer [98,99].
Azacitidine and decitabine (5-aza-2 deoxycytidine) are
cytidine analogs in which the carbon atom at position 5 in
the pyrimidine ring has been replaced by a nitrogen atom.Following cellular uptake, azacitidine and decitabine are
converted into their corresponding monophosphates, di-
phosphates, and triphosphates nucleotides. As nucleotide
analogues, they replace cytosine during DNA replication,
producing DNA demethylation by inactivation of DNMTs.
Despite indiscriminately targeting DNMTs [100], they were
found at low dosages to selectively reactivate gene expres-
sion with relatively few side effects [101]. Incorporation into
the DNA results in the formation of adducts between the
DNA and DNMT. Although at high doses, the DNA is not
able to recover and cell death occurs, at lower doses the
formed adducts are degraded by the proteosome, after
which the DNA is restored. DNA synthesis is then resumed
in the absence of DNMT, and as a consequence the aber-
rant DNA methylation pattern can no longer be established
in the DNA daughter strands. In this manner, a low dose of
azacitidine or decitabine is able to induce re-expression of
previously silenced genes [102-104].
Clinical drugs targeting histone modifications
Several clinical trials of histone deacetylase inhibitors
(HDACi) have been conducted in solid and hematological
malignancies. Interestingly, until now the results demon-
strate a preferential efficacy in hematological malignancies
[105]. These compounds are also beginning to be tested in
combination therapies, either as chemo sensitizing agents
in association with standard chemotherapy drugs or in
combination with DNA methyl transferase inhibitors
(Table 1). In human, the biological target of HDACi, the
histone deacetylases complexes (HDACs), comprise a
family of 18 genes sub-divided into 4 classes based on
their sequence homology to yeast proteins, sub-cellular
localization and enzymatic activities [106]. HDAC belong-
ing to class I (HDAC1, HDAC2, HDAC3 and HDAC8),
class IIa (HDAC4, HDAC5, HDAC7 and HDAC9), class
IIb (HDAC6 and HDAC10) and class IV (HDAC11)
exhibit a Zn dependent enzymatic activity, which is
the bases of their interaction with the HDACi currently
used. Class III (or Sirtuins) constitute a structurally separ-
ate subfamily which exhibit a NAD-dependent enzymatic
activity.
HDACi can be classified based on their general chemical
structure in short fatty acid, cyclic peptide benzamide and
hydroxamic acids (Table 1). These inhibitors differ in po-
tency, pharmacokinetic properties and, more importantly,
on their selectivity to inhibition targets. According to their
in vitro selectivity profile, HDACi are classified in pan
HDACi, which inhibit HDAC class I and II (e.g. vorinostat,
panobinostat and belinostat), or selective HDACi, which
inhibit either HDAC class I (e.g. mocetinostat, entinostat)
or class II (e.g. MC1568) [107]. It is generally accepted that
particular attention should be paid to HDACi inhibition
selectivity in the interpretation of experimental re-
sults; although it must be stress that the selectivity
Table 1 Selected histone deacetylase inhibitors





Phenylbutyrate Short fatty acid
chain
Pan-inhibitor 0/6 0
Valproic acid Short fatty acid
chain
ClassI/IIa 5/14 1/7
Vorinostat (SAHA) Hydroxamic acid Pan-inhibitor 8/25 2/4
Belinostat (PXD101) Hydroxamic acid Pan-inhibitor 1/4 0/1
Panobinostat (LBH589) Hydroxamic acid Pan-inhibitor 7/11 2/3
Trichostatin A Hydroxamic acid Pan-inhibitor 0 0
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Table 1 Selected histone deacetylase inhibitors (Continued)
Givinostat (ITF2375) Hydroxamic acid Pan-inhibitor 0 0
Mocetinostat
(MGCD0103)
Benzamide Class I/IV 0/3 0/1
Entinostat
(MS275-SNDX275)
Benzamide Class I 2/7 1/3
Romidepsin
(Depsipeptide)
Cyclic tetrapeptide Class I 0/5 0/1
Trapoxin B Cyclic tetrapeptide Class I/IIa 0 0
Chemical structures from http://www.chemspider.com.
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http://www.jhoonline.org/content/6/1/57profile has been mainly determined in vitro and
therefore may not reflect the physiological state of
HDACs. Moreover, it is still unknown if a selective
HDACi could have a better balance among desired
and undesired effect than a pan HDACi.
The effects of HDAC inhibitors appear to be to pro-
mote G1 or G2/M cell-cycle arrest, as well as apoptosis
and cell differentiation. It is important to keep in mind
that histone are not the only targets of HDAC, but
among their know substrates are also included p53, sig-
nal transducer and activator of transcription 3 (STAT3),
heat shock protein 90 (hsp 90), and other important pro-
teins and therefore changes in the acetylation status of
these other proteins may contribute to the biological ef-
fects observed [108].
Only two HDACi have been approved by the FDA:
Vorinostat for the treatment of cutaneous T cell lymphoma
(CTCL) on October 6, 2006, which has also given encour-
aging results in a phase II trial for MDS in combination
with Idarubicin and Cytarabine, and Romidepsin for CTCL
on November 5, 2009. However, there are several more
been tested in phase I, II or III for different diseases. Cur-
rently, according to Clinical Trials Database (www.
clinicaltrials.gov), for AML treatment there are ongoing
clinical trials for: valproic acid, vorinostat, belinostat,
panobinostat and etinostat either alone or in combin-
ation with the DNA methylation inhibitor 5-azacytidine
(decitabine) (Table 1).
Somehow unexpectedly, HAT inhibitors have also been
shown to have some antitumor activity. This contrasts with
the global hypoacetylation already seen in many cancers.
Naturally occurring drugs such as curcumin, garcinol, and
anacardic acid appear to selectively inhibit the acetyl trans-
ferases p300, CBP, or PCAF, leading to apoptosis or
sensitization to therapies such as radiation [109-111]. Until
know no clinical trials have yet been completed with this
class of agents.
Epigenetic based therapies have so far focused on the
use of DNMTs and HDACs inhibitors, which tend to
have more general and widespread effects on gene regu-
lation in the cell. However, if a unique molecular
pathway can be identified in diseases caused byTable 2 Selected strategies using epigenetic tools for leukem
for Patents of Inventions
Patent document Target gene




US2009317801 Genes located on the long arm
of chromosome 17 (17q25.3)
An
US2011281270 CEBPA Deepigenetic mechanisms, they will be excellent candi-
dates for the development of more targeted therapies
that focus on specific gene targets, individual binding
domains, or specific enzymatic activities. Therefore,
designing effective targeted therapies depends on a clear
understanding of the role of epigenetic mutations during
disease progression.
AML Epigenetics: patent applications and granted patents
In this section we summarize, current information publi-
cally available in the international system of Patents of
Inventions registered mainly at the World Intellectual
Property Office (WIPO, http://www.wipo.int/portal/index.
html.en) as well as at the european (http://worldwide.
espacenet.com), the japanese (http://www.jpo.go.jp/) and
the US (http://patft.uspto.gov/) patents offices. Briefly,
patents applications are those still in analysis to define if
they will be or not granted, but we include them as a sam-
ple of the efforts to develop new technological strategies
against AML and its epigenetics causes. Tables 2 and 3
summarize patent documents related to the epigenetic
tools currently proposed for AML diagnostic and thera-
peutic strategies.
Conclusions
Despite recent major advances in our understanding of
the genetics of myeloid malignancies, there have been
far fewer examples of how these insights have been
translated to novel therapies. Epigenetic modifiers pro-
vide new targets for therapeutic intervention. Mutations
in IDH1 and IDH2 that result in a new enzymatic ac-
tivity may represent novel, tractable targets for this
genetically defined subset of leukemia patients. Like-
wise, enzymatic activities associated with genes in-
volved in leukemic transformation (including H3K79
methyltransferase activity, histone acetyltransferase ac-
tivity and other chromatin enzymatic functions) have
just recently been explored from a therapeutic stand-
point. Worldwide scientific and patents of inventions
literature, suggest that advances in our knowledge of
the genetics of myeloid malignancies, coupled with an
improved understanding of the role of specificia diagnostic as proposed in the International Database
Method based on
tection of five point mutations in HDAC1: M51L, Q111K, T114A, V157G
a premature stop codon at R34
tection of one or more mutations, mainly at Arg-882
tection of expression levels or mutations in this putative suppressor gene
alysis of methylation state of a target gene in this chromosomal region
tection of bi allelic mutations in CCAAT-enhancer binding protein gene
Table 3 Selected compounds proposed as epigenetic tools for leukemia treatment according to the International
Database for Patents of Inventions
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http://www.jhoonline.org/content/6/1/57epigenetic modifications in leukemogenesis, may
probably lead to an increased number and/or progress
in the development of therapies that improve out-
comes for patients with MPN, MDS and AML in fu-
ture years. Moreover, there is hope that this
knowledge could also give rise to new diagnostic and/or prognostic methods allowing the design of a per-
sonalized treatment for each patient, as well as more
sensitive procedures to detect the pathologies sooner,
which is particularly relevant considering that some
of the most common cancer types are largely curable
if they are detected early and treated appropriately.
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